{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:11:11Z","timestamp":1767337871893,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"am","delay-in-days":330,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ygyno.2023.08.004","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T16:58:32Z","timestamp":1693069112000},"page":"60-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment"],"prefix":"10.1016","volume":"177","author":[{"given":"Wei","family":"Ao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Im","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenic","family":"Tommarello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly A.","family":"Conrads","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L.","family":"Hood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Litzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Abulez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pang-Ning","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifton L.","family":"Dalgard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Wilkerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Tarney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil T.","family":"Phippen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Bakkenist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Larry","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Conrads","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John I.","family":"Risinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas W.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.08.004_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"year":"2023","author":"SEER","series-title":"SEER Stat Fact Sheets: Ovary Cancer","key":"10.1016\/j.ygyno.2023.08.004_bb0010"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0015","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0020","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2014.12.035","article-title":"Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells","volume":"136","author":"Teng","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0025","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.01.007","article-title":"DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis","volume":"332","author":"Roos","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0035","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","article-title":"Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint","volume":"14","author":"Liu","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0040","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","article-title":"ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1","volume":"21","author":"Zhao","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0045","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/cdd.2013.5","article-title":"CDC25A targeting by miR-483-3p decreases CCND-CDK4\/6 assembly and contributes to cell cycle arrest","volume":"20","author":"Bertero","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0050","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.14.4.397","article-title":"ATR disruption leads to chromosomal fragmentation and early embryonic lethality","volume":"14","author":"Brown","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0055","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41467-017-01401-x","article-title":"ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and and-1","volume":"8","author":"Moiseeva","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0060","doi-asserted-by":"crossref","first-page":"ii8","DOI":"10.1093\/annonc\/mdv084.3","article-title":"O6.3ATR inhibitor AZD6738","volume":"26","author":"Clack","year":"2015","journal-title":"Ann. Oncol."},{"issue":"42","key":"10.1016\/j.ygyno.2023.08.004_bb0065","doi-asserted-by":"crossref","first-page":"44289","DOI":"10.18632\/oncotarget.6247","article-title":"The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo","volume":"6","author":"Vendetti","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0070","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","article-title":"ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency","volume":"74","author":"Mohni","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0075","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","article-title":"An update on PARP inhibitors--moving to the adjuvant setting","volume":"12","author":"Sonnenblick","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0085","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0090","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1158\/1078-0432.CCR-22-0568","article-title":"Identification of a molecularly-defined subset of breast and ovarian Cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance","volume":"28","author":"Serra","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/bjc.2013.687","article-title":"Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes","volume":"110","author":"Teng","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.066","article-title":"Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer","volume":"31","author":"Lee","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0105","first-page":"222","article-title":"Effect of alpha-difluoromethylornithine (DFMO) on the growth of human ovarian carcinoma","volume":"9","author":"Manetta","year":"1988","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1290\/1071-2690(2000)036<0357:COFNEO>2.0.CO;2","article-title":"Characterization of four novel epithelial ovarian cancer cell lines","volume":"36","author":"Provencher","year":"2000","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0115","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2016.03.006","article-title":"A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors","volume":"62","author":"Ruiz","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0120","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/pmic.201400316","article-title":"Dynamics of zebrafish fin regeneration using a pulsed SILAC approach","volume":"15","author":"Nolte","year":"2015","journal-title":"Proteomics"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0125","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1074\/mcp.RA118.000583","article-title":"Peptide level turnover measurements enable the study of Proteoform dynamics","volume":"17","author":"Zecha","year":"2018","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-4419-5635-4_8","article-title":"The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease","volume":"703","author":"Tsybovsky","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/cr.2007.15","article-title":"Use of arrays to investigate the contribution of ATP-binding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity","volume":"17","author":"Zhang","year":"2007","journal-title":"Cell Res."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0140","series-title":"American Association for Cancer Research Annual Meeting. Philadelphia, PA","article-title":"Targeting ATR using a novel ATR inhibitor AZD6738 in human gastric cancer cells","author":"Ahrum Min","year":"2015"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0145","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1038\/onc.2016.506","article-title":"CyclinD-CDK4\/6 complexes phosphorylate CDC25A and regulate its stability","volume":"36","author":"Dozier","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0150","doi-asserted-by":"crossref","first-page":"8665","DOI":"10.1093\/nar\/gkab628","article-title":"Loss of cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress","volume":"49","author":"Lloyd","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0155","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1158\/0008-5472.CAN-21-4335","article-title":"Resistance to ATR inhibitors is mediated by loss of the nonsense-mediated decay factor UPF2","volume":"82","author":"O\u2019Leary","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41389-020-00270-2","article-title":"Overexpression of cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors","volume":"9","author":"Kok","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103988","article-title":"Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes","volume":"9","author":"Beaufort","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0170","doi-asserted-by":"crossref","first-page":"21767","DOI":"10.1074\/jbc.M300229200","article-title":"Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents","volume":"278","author":"Xiao","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.rmed.2016.03.011","article-title":"Increased serum VDBP as a risk predictor for steroid resistance in asthma patients","volume":"114","author":"Jiang","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0180","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.ygyno.2023.08.004_bb0185","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ccell.2023.02.004","article-title":"Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer","volume":"41","author":"Bancaro","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109844","article-title":"Targeting TREM2 on tumor-associated macrophages enhances immunotherapy","volume":"37","author":"Binnewies","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0195","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","article-title":"Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer","volume":"17","author":"Konecny","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.08.004_bb0200","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research, N","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2023.08.004_bb0205","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823014336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823014336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:04:34Z","timestamp":1758773074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823014336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":41,"alternative-id":["S0090825823014336"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.08.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}